0.00
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bio Path Holdings
Its shares trade under the ticker BPTH. It has been listed since 11 January 2006. In the fiscal year to 31 December 2017, it reported revenue of $37,000 and a net loss of $7.0m. At that date it held total assets of $8.9m and shareholders' equity of $8.1m.
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The company is headquartered in Bellaire, Texas. The company went IPO on 2006-01-11. The firm utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The firm's drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. In vivo, the DNAbilize delivered antisense drug substances are systemically distributed across the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize as a platform for drug manufacturing, the Company has approximately three antisense drug candidates in development to treat a total of over five different cancer disease indications.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Jan 2006
- Employees
- 10
- Website
- biopathholdings.com ↗
- Head office
- 4710 BELLAIRE BOULEVARD, BELLAIRE, TX, 77401
- Incorporated in
- WY
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Vikram GroverPresident, Chief Executive Officer, Chief Financial Officer, Director, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biotechnology company with DNAbilize platform for targeted protein inhibition in blood diseases.
- Developing three antisense drug candidates for over five cancer disease indications.
- 10 full-time employees focused on AML and CML therapies development.
Weaknesses
- Headquartered in Bellaire, Texas with limited local biotech infrastructure.
- Only three drug candidates in development for multiple cancer indications.
- IPO listed in 2006 with no recent market expansion details.
Opportunities
- Expanding DNAbilize platform to new cancer disease indications beyond current five.
- Growing biotechnology sector in the US for leukemia therapies.
- Collaborating with US healthcare institutions for clinical trials.
Threats
- Competition from established biotech firms in leukemia treatment market.
- Regulatory challenges in drug approval processes for new therapies.
- Economic downturns affecting biotech investment funding.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.